Building resilience in pharmaceutical supply chains amid geopolitical risk

AI Summary

Pharmaceutical companies are adapting to geopolitical risks by reducing their dependency on active pharmaceutical ingredients sourced from foreign nations. They are reshoring manufacturing and enhancing supply chain resilience to maintain production quality and availability by 2026.

How pharma companies manage geopolitical risks, reduce API dependency, reshore manufacturing and build resilient supply chains for 2026 and beyond.